Entera Bio

Entera Bio Asset Growth

The Year-over-Year Total Asset Growth of Entera Bio (ENTX) as of Nov 22, 2026 is 70.32 %. In the previous year, Year-over-Year Total Asset Growth was -20.19 % — a change of -448.34% (higher).

Asset Growth

70.32 %

YoY

-448.34%

Last updated:

Year-over-Year Total Asset Growth of Entera Bio is 2025 70.32 % . Year-over-Year Total Asset Growth of Entera Bio was 2024 -20.19 % . It decreases by -448.34% higher compared to the previous year.

The Entera Bio Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2018
0.47 USD
Jan 1, 2019
25.20 USD
Jan 1, 2020
-41.79 USD
Jan 1, 2021
167.30 USD
Jan 1, 2022
-49.49 USD
Jan 1, 2023
-10.38 USD
Jan 1, 2024
-20.19 USD
Jan 1, 2025
70.32 USD
The Entera Bio Asset Growth history
YEARAsset GrowthYoY
70.32 %-448.34%
-20.19 %+94.56%
-10.38 %-79.03%
-49.49 %-129.58%
167.30 %-500.29%
-41.79 %-265.85%
25.20 %+5,211.31%
0.47 %-99.57%
111.23 %-13.66%
128.83 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Entera Bio Stock analysis

What does Entera Bio do? Entera Bio Ltd is an emerging biotechnology company focused on developing oral medications to treat unmet medical needs. The company was founded in 2010 and is headquartered in Jerusalem, Israel. Its history began with the discovery of the "EnteraGam" molecule in the intestinal cells of breastfed infants, which helps them fight infections. This led to the development of EnteraGam for the treatment of various autoimmune diseases. The company's business model is based on developing oral formulations for existing drugs and discovering and developing new molecules. Its focus areas are osteoporosis, hypoparathyroidism, chronic kidney disease, and autoimmune diseases. Entera Bio is divided into three business divisions: the Oral Protein Delivery Platform, the Oral Parathyroid Hormone (PTH) Platform, and the Collagen-based Platform for Wound Healing. Its products include EB611, a candidate for hypoparathyroidism treatment, EB613 for osteoporosis treatment, and EB612 for chronic kidney disease. These products have potential to improve the lives of millions of patients worldwide. Entera Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Entera Bio stock

Year-over-Year Total Asset Growth of Entera Bio is 70.32 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Entera Bio since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Entera Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Entera Bio

All Key Metrics — Entera Bio